Carl read the papersWhat it actually is
Chonluten is a synthetic tripeptide, Glu-Asp-Gly (EDG), from the St Petersburg bioregulator programme. Lab papers call it T-34. In Russia it is registered as an oral capsule dietary supplement.
It is marketed for bronchial and lung tissue, which puts it next to Bronchogen on the shelf. The developers also describe it as a gastroprotector and a stress-protector, which tells you how loosely 'tissue-specific' gets applied in this family.
How it’s thought to work
- Inflammation dial-down — In a human monocyte cell line, Chonluten cut TNF release after a bacterial (LPS) challenge. All five peptides in that study also reduced TNF and IL-6 in mature macrophages.
- Stomach lining — In a gastric-ulcer model, T-34 normalised the expression of antioxidant and anti-inflammatory genes.
- Stress response — The developer's patent reports effects on stress-gene (c-Fos) activity in rat brains and better tolerance of simulated altitude in young men.
- Gene regulation — The family premise: short peptides reach the nucleus and change gene activity. Supported by cell work and modelling, not human measurements.
What the research says
Small and scattered. The best-designed paper is an Italian cell study (with Khavinson as co-author) showing Chonluten reduced TNF from inflamed monocytes. A 2012 Russian paper covers gene expression in gastric ulcer. The developer's US patent reports 80 young men at a simulated 5,000 m: 80 to 90% of the peptide groups tolerated it well against 60% on placebo, with no mention of blinding or randomisation. A 2020 review by the developers says oral EDG works in COPD and chronic bronchitis, but that paragraph cites no trial, only the gastric-ulcer gene paper. No registered human trial exists.
- Khavinson-family tripeptide (EDG, lab code T-34), sold for bronchial and lung tissue; oral supplement in Russia.
- Cell study: reduced TNF from LPS-stimulated human monocytes.
- Patent: 80 young men at simulated 5,000 m altitude, better tolerance reported vs placebo; blinding not stated.
- COPD and chronic bronchitis claims appear in the developers' review without a cited trial.
Reported protocols
These are the doses the peptide community actually reports running (Reddit & forums), alongside published research — logged for education, not as a recommendation to use.
| Parameter | Commonly reported range |
|---|---|
| Community dose | Not established. We found no vendor-independent user reports. |
| Developer's patent | Claims 0.01 to 100 mcg per kg at least once daily, by injection or nasal drops. The altitude study used 1 mcg, 100 mcg or 5 mg, by nose three times a day or into muscle once a day, for two days. |
| Russian product | Oral capsule supplement. The registry entry we checked lists the amino acids, not the amount per capsule. |
| Carl's note | Breathing problems are where self-experimenting goes wrong fastest. Get a lung function test first. |
Common use cases
| Goal | Community protocol notes |
|---|---|
| Bronchial and lung support | the marketed use; the COPD claim is not backed by a cited trial |
| Stress or altitude tolerance | from the developer's patent study in young men |
| Alongside Bronchogen | the two respiratory peptides in the family |
Mixing it (reconstitution)
Freeze-dried peptides must be reconstituted with bacteriostatic water before they can be measured. Carl’s calculator turns “mg in the vial + ml of water + target dose” into “units on the syringe” — and tells you how long the vial lasts.
→ Open the Reconstitution Calculator
Injection & handling
No human dose has been established. The developer's patent used intramuscular and intranasal dosing in a two-day altitude study and claims a per-kilogram range; the Russian product is a capsule. Research powder is often sold for injection, with no study behind any specific amount. If it is used anyway, standard vial hygiene applies. A cough that won't quit, wheeze or breathlessness needs a lung function test and a diagnosis first.
Stacks it appears in
- With Bronchogen — The family's two respiratory peptides. The developers' 2020 review discusses them together; no study tests the combination.
- With Thymosin Alpha-1 — Both turn up in immune and inflammation discussions, through quite different mechanisms.
Sources
- NCBI MeSH: glutamyl-aspartyl-glycine [Supplementary Concept]
- Khavinson et al. 2022, Transport of biologically active ultrashort peptides using POT and LAT carriers (Int J Mol Sci)
- Khavinson et al. 2020, Peptides: prospects for use in the treatment of COVID-19 (Molecules)
- Khavinson et al. 2012, Peptide regulation of genes encoding antioxidant and anti-inflammatory proteins
- Avolio et al. 2022, Peptides regulating proliferation and inflammatory pathways in THP-1 monocytes/macrophages
- Patent US8071556B2: peptide substance with stress-protective effect (H-Glu-Asp-Gly-OH)
- Khavinson et al. 2023, Transport of 26 ultrashort peptides via LAT and PEPT transporters (Biomolecules)
- RLS (rlsnet.ru) registry: Khonluten, dietary supplement (BAD)
- SAHPRA, Peptide Products: Public Information (May 2026)
- WADA Prohibited List 2026 (S0 and S2.2.1)
- ClinicalTrials.gov search: chonluten
